Sharifzadeh Mohammad, Ramazani Farid, Shamsa Fazel
Department of Pharmacology & Toxicology, Tehran University of Medical Sciences, PO Box 14155-6451, Tehran, Iran.
Eur J Pharm Sci. 2004 Apr;21(5):575-9. doi: 10.1016/j.ejps.2003.12.008.
Three compounds (C1, C2 and C3) were synthesized by reacting dexamethasone as a strong anti-inflammatory drug or prednisolone as a moderate one with 1,3-butadiene under Diels-Alder reaction conditions to produce pentacyclic compounds. The structures of C1 [(11 beta,16 alpha,17 alpha)-9 alpha-fluoro-11,17,21-trihydroxy-16-methyl pregna [1 alpha,2 beta]-cyclohex 3',4-diene, 3,20-dione], C2 [(11 beta,16 alpha,17 alpha)-9 alpha-fluoro-11,17,21-trihydroxy-16-methyl pregna [1 alpha,2 alpha]-cyclohex 3',4-diene, 3,20-dione], and C3 [(11 beta,17 alpha)-11,17,21-trihydroxy-pregna [1 alpha,2 alpha]-cyclohex 3',4-diene, 3,20-dione] were concluded based on GC-mass and 1H NMR spectroscopic data. The compounds were used to evaluate the effect of introducing extra ring in the structure of the above drugs on their anti-inflammatory behavior. The potencies of the three compounds were compared with that of the mother drugs by the rat hind paw edema test. The results indicate a decrease in C1 potency, expressed as percentage of inflammation inhibition (16.5% versus 24.3% for Dex) or loss of C2 potency (2.0% versus 24.3% for Dex) in dexamethasone adducts. On the other hand, although the prednisolone adduct C3 lost potency too (3.95% versus 26.3% for Pred), but instead it lowered significantly the prednisolone potency on subsequent administration before prednisolone (C3+Pred) (1.30% versus 17.10% for Pred). When prednisolone was administered in equal doses after C3 (10mg/kg), it restored about 60% of its activity. This observation indicates that C3 still retain affinity toward GR without eliciting subsequent events. In other words it has anti prednisolone effect, i.e. anti-glucocorticoid property.
通过使作为强效抗炎药的地塞米松或作为中效抗炎药的泼尼松龙与1,3 - 丁二烯在狄尔斯 - 阿尔德反应条件下反应,合成了三种化合物(C1、C2和C3),以生成五环化合物。根据气相色谱 - 质谱和1H NMR光谱数据确定了C1 [(11β,16α,17α)-9α - 氟 - 11,17,21 - 三羟基 - 16 - 甲基孕甾[1α,2β] - 环己3',4 - 二烯,3,20 - 二酮]、C2 [(11β,16α,17α)-9α - 氟 - 11,17,21 - 三羟基 - 16 - 甲基孕甾[1α,2α] - 环己3',4 - 二烯,3,20 - 二酮]和C3 [(11β,17α)-11,17,21 - 三羟基 - 孕甾[1α,2α] - 环己3',4 - 二烯,3,20 - 二酮]的结构。这些化合物用于评估在上述药物结构中引入额外环对其抗炎行为的影响。通过大鼠后爪水肿试验比较了这三种化合物与母体药物的效力。结果表明,地塞米松加合物中C1的效力降低,以炎症抑制百分比表示(地塞米松为16.5%对24.3%)或C2失去效力(地塞米松为2.0%对24.3%)。另一方面,虽然泼尼松龙加合物C3也失去了效力(泼尼松龙为3.95%对26.3%),但在泼尼松龙之前随后给药时,它显著降低了泼尼松龙的效力(C3 + 泼尼松龙,泼尼松龙为1.30%对17.10%)。当在给予C3(10mg/kg)后以等剂量给予泼尼松龙时,它恢复了约60%的活性。该观察结果表明C3仍然保留对糖皮质激素受体(GR)的亲和力而不引发后续事件。换句话说,它具有抗泼尼松龙作用,即抗糖皮质激素特性。